Kushner Tatyana, Khungar Vandana
Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA.
Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA, USA.
Clin Liver Dis. 2015 Nov;19(4):629-39, v-vi. doi: 10.1016/j.cld.2015.06.004.
Over the past few years, tremendous advances have been made in the treatment of hepatitis C with direct-acting antiviral agents (DAAs), allowing treatment options for patients who have failed prior treatment with interferon. In addition to interferon's severe adverse effect profile, and the inability of many patients to tolerate it, prior interferon-containing regimens were not as effective in achieving sustained virologic response as emerging therapies. New DAAs have demonstrated higher rates of sustained virologic response, shorter duration of treatment, and improved adverse effect profile.
在过去几年中，直接作用抗病毒药物（DAAs）在丙型肝炎治疗方面取得了巨大进展，为先前使用干扰素治疗失败的患者提供了治疗选择。除了干扰素严重的不良反应以及许多患者无法耐受之外，先前含干扰素的治疗方案在实现持续病毒学应答方面不如新兴疗法有效。新型直接作用抗病毒药物已显示出更高的持续病毒学应答率、更短的治疗疗程以及改善的不良反应情况。
